Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis

Numerous studies have identified that the slow acetylation status of N-acetyltransferase 2 (NAT2) is associated with an elevated bladder cancer risk. However, the results remain inconclusive. The aim of our study was to evaluate the effect of NAT2 acetylation status in patients with bladder cancer.

Electronic databases were searched to retrieve related studies published in the past decade. The pooled odds ratio (OR) with its 95% confidence interval (CI) was used to calculate the strength of this relationship. Overall, a total of 18 studies were selected for the analysis, which included 4473 bladder cancer cases and 7204 matched controls. Our result showed that the NAT2 slow acetylation phenotypes were significantly associated with an increased risk of bladder cancer compared with the rapid phenotypes (OR, 1. 56; 95% CI, 1. 33-1. 82; P < . 00001) in a random-effect model. This significant association was also found in a subgroup analysis of ethnicity (P < . 05). Furthermore, the NAT2 slow phenotypes also significantly increased the risk of bladder cancer in smokers (OR, 0. 75; 95% CI, 0. 62-0. 90; P = . 002). However, no correlation was found between the combined effect of NAT2 slow phenotypes and gender with bladder cancer risk (OR, 0. 89; 95% CI, 0. 28-2. 78; P = . 84). In conclusion, our results suggest that the NAT2 slow acetylator, in particular, the NAT2 slow acetylator combined with smoking, are associated with an increased bladder cancer risk. Future well-designed studies with large populations and more ethnicities are needed to clarify this association further.

Clinical genitourinary cancer. 2015 Oct 26 [Epub ahead of print]

Haoran Wu, Xugang Wang, Liang Zhang, Naixin Mo, Zhong Lv

Department of Urology, Wujin Hospital, Affiliated to Jiangsu University, Changzhou, People's Republic of China. , Department of Urology, Wujin Hospital, Affiliated to Jiangsu University, Changzhou, People's Republic of China. , Department of Urology, Wujin Hospital, Affiliated to Jiangsu University, Changzhou, People's Republic of China. , Department of Urology, Wujin Hospital, Affiliated to Jiangsu University, Changzhou, People's Republic of China. Department of Urology, Wujin Hospital, Affiliated to Jiangsu University, Changzhou, People's Republic of China. 

PubMed